Radioisotopes

"Radioisotopes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)

Descriptor ID	D011868
MeSH Number(s)	D01.496.749
Concept/Terms	Radioisotopes Radioisotopes Radioactive Isotopes Isotopes, Radioactive Radionuclides Daugter Isotopes Daugter Isotopes Isotopes, Daugter Radiogenic Isotopes Isotopes, Radiogenic Daughter Nuclides Nuclides, Daughter

Below are MeSH descriptors whose meaning is more general than "Radioisotopes".

Chemicals and Drugs [D]
Inorganic Chemicals [D01]
Isotopes [D01.496]
Radioisotopes [D01.496.749]

Below are MeSH descriptors whose meaning is related to "Radioisotopes".

Below are MeSH descriptors whose meaning is more specific than "Radioisotopes".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Radioisotopes" by people in this website by year, and whether "Radioisotopes" was a major or minor topic of these publications.

Bar chart showing 40 publications over 20 distinct years, with a maximum of 4 publications in 2001 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	2	1	3
2000	1	0	1
2001	1	3	4
2002	0	2	2
2005	1	1	2
2006	0	1	1
2008	0	2	2
2009	1	1	2
2010	1	1	2
2013	0	1	1
2014	0	2	2
2015	0	2	2
2016	1	2	3
2017	1	3	4
2018	0	1	1
2020	0	1	1
2021	1	1	2
2022	0	1	1
2023	0	3	3
2024	0	1	1

Below are the most recent publications written about "Radioisotopes" by people in Profiles.

Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fl?chon A, Wei XX, Mahammedi H, Roubaud G, ?tudentov? H, Nagarajah J, Mellado B, Montesa-Pino ?, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024 09 28; 404(10459):1227-1239.

View in: PubMed
Sethi HK, Sina EM, Mady LJ, Fundakowski CE. Sentinel lymph node biopsy for head and neck malignancies utilizing simultaneous radioisotope gamma probe and indocyanine green fluorescence navigation. Head Neck. 2024 01; 46(1):212-217.

View in: PubMed
Seldon C, Grossman JG, Shrivastava G, Fernandez M, Jin W, Conaway S, Rosenberg A, Livingstone A, Franceschi D, Jonczak E, Trent J, Subhawong T, Studenski MT, Yechieli R. CivaSheet? use for soft tissue sarcoma: A single institution experience. Brachytherapy. 2023 Sep-Oct; 22(5):649-654.

View in: PubMed
Gudenkauf LM, Chavez MN, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. J Nucl Med. 2023 06; 64(6):869-872.

View in: PubMed
George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandstr?m P, Verholen F, Higano CS, Shore N. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer Prostatic Dis. 2022 02; 25(2):306-313.

View in: PubMed
Harkenrider MM, Albuquerque K, Brown D, Kamrava M, King M, Mourtada F, Orio P, Patel R, Price M, Rassiah P, Solanki AA, Small W, Schechter NR. ACR-ABS-ASTRO practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy. Brachytherapy. 2021 Nov-Dec; 20(6):1071-1082.

View in: PubMed
Frantz S, Matsuoka L, Vaheesan K, Petroziello M, Golzarian J, Wang E, Gandhi R, Collins Z, Brower J, Rachakonda VM, Du L, Kennedy AS, Sze DY, Lee J, Brown DB. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry. J Vasc Interv Radiol. 2021 06; 32(6):845-852.

View in: PubMed
Hurwitz M, Buscombe JR, Jacene HA, Klitzke AK, Lamonica D, Lu Y, Pryma DA, Rohren EM, Speer TW, Subramaniam RM, Thompson HM, Tomblyn MB, Wong WW, Xiao Y, Banks KP, Brown RKJ. ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. Am J Clin Oncol. 2020 08; 43(8):539-544.

View in: PubMed
Jacene H, Gomella L, Yu EY, Rohren EM. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations. Clin Genitourin Cancer. 2018 08; 16(4):e919-e926.

View in: PubMed
Shore ND, Tutrone RF, Mariados NF, Nordquist LT, Mehlhaff BA, Steere KJ, Harrelson SS. eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2018 04; 16(2):149-154.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement